Oncotarget changed its schedule at the start of the year, and so the online biomedical journal ill be having new publications two times a week. Almost all of the issues from the current volume eight which are 36 so far will be available in the scientific archive of PubMed as soon as the Scientific Libary of medicine is finished with processing it. It has been a long time goal for Oncotarget to submit an issue as soon as it becomes available online and they are very close to accomplishing that goal.
Other archives where the journal of Oncotarget can e accessed ar Scopus, PubMed Central, BIOSIS Preview, ISI/ Web of Science: Science Citation Index Expanded, Biological Abstracts, and EMBASE. Working with the National Library of Medicine and several indexes, Oncotarget has been able to increase the accuracy of the data and information published in the journal. The reader base of the Oncotarget online biomedical journal is made up of practitioners, researchers in the medical and biomedical field among others, as well as the general public. Oncotarget aims at reaching a wide audience which is why the issues of the journal are open-access. Learn more about Oncotarget at researchgate.net
The journal puts a strong emphasis on oncology, but it also published research papers in the fields of immunology, chromosomes, microbiology, autophagy, pathology, aging, and several other areas. The journal might e increasing its fields of coverage in the future. Each of the fields of study has its own editorial board with experts who do peer-reviews. Some of the editorial board are larger than others. The Autophagy and Cell Death Section Advisory Board, for example, has more than a hundred experts. Follow Oncotarget on Linkedin.
The Oncotarget journal also has a Founding Editorial Board of more than a dozen people as well as two Editors in Chief. Both from the Roswell Park Cancer Institute in Buffalo, New York, the editors in chief have been occupying the position for several years. Dr. Andrei V. Gudkov specializes in cancer research and molecular biology. Dr. Mikhail Blagsklonny works in oncology as well as biogerontology, which is the science of aging. He is also an Associate Editor for several other journals.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/